Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 2

Results For "combination-products"

18 News Found

NATCO launches Chlorantraniliprole combination agro products in India
News | October 05, 2022

NATCO launches Chlorantraniliprole combination agro products in India

Both products are broad-spectrum, foliar insecticides used across wide range of crops


Pharmapack Europe 2022 to open on May 18-19 in Paris
Packaging | April 12, 2022

Pharmapack Europe 2022 to open on May 18-19 in Paris

Pharmapack trends are a key barometer of global device and packing opportunities in 2022


Lonza Joins International Pharmaceutical Aerosol Consortium
News | April 01, 2022

Lonza Joins International Pharmaceutical Aerosol Consortium

Through this consortium, Lonza will collaborate with other industry leaders to advance the research and development of inhalation technologies


UFDA approves first generic of Symbicort to treat asthma and COPD
Drug Approval | March 16, 2022

UFDA approves first generic of Symbicort to treat asthma and COPD

This drug-device combination product is a metered-dose inhaler (MDI), which contains both budesonide (a corticosteroid that reduces inflammation) and formoterol (a long-acting bronchodilator that relaxes muscles in the airways to improve breathing)


HCmed, Formosa Laboratories, and Formosa Pharmaceuticals form CDMO
Biotech | March 07, 2022

HCmed, Formosa Laboratories, and Formosa Pharmaceuticals form CDMO

According to statistics, the global inhalation drug market reached US $ 25 billion in 2020


IFF to acquire contract manufacturer of dietary supplements Health Wright Products
News | February 22, 2022

IFF to acquire contract manufacturer of dietary supplements Health Wright Products

The sale is expected to close in the first quarter of 2022


Zydus Cadila awaits product approvals worth US $6 billion
News | January 21, 2021

Zydus Cadila awaits product approvals worth US $6 billion

With cost optimization leading to cumulative savings of US $80 million over last 8 years, the company now aims to tap bigger opportunities in generics business